文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

2006至2021年风湿与肌肉骨骼疾病患者阿片类药物处方趋势及COVID-19大流行的影响

Trends for opioid prescribing and the impact of the COVID-19 pandemic in patients with rheumatic and musculoskeletal diseases between 2006 and 2021.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

研究纳入英国初级保健中2006年1月1日至2021年8月31日期间无癌症的成人风湿与肌肉骨骼疾病(RMD)患者1 313 519例,分析阿片类药物处方趋势及COVID-19大流行的影响。结果显示,2018年后多数RMD阿片类药物使用趋于平稳或下降,大流行期间大多数RMD阿片类药物使用者减少,未出现处方骤增。

要点

  • 2006至2018/2019年,RA、PsA和FM新阿片类药物使用者增加,2021年回落。
  • 2006至2021年,所有RMD的MME/天增加,FM最高(≥35)。
  • 大流行期间大多数RMD阿片类药物使用者减少,无骤增。

核心结论

  • 2018年后RMD阿片类药物使用者趋于平稳或下降,可能反映英国应对阿片处方增长的努力。
  • 大流行导致大多数RMD阿片类药物使用者减少,未出现处方骤增。

研究设计与样本

  • 基于英国初级保健数据的观察性研究,纳入2006年1月1日至2021年8月31日期间无癌症的成人RA、PsA、中轴型脊柱关节炎(AxSpA)、SLE、OA和FM患者,共1 313 519例。
  • 计算2006至2021年年化的年龄和性别标化新发及现患阿片类药物使用者率,以及现患使用者月均吗啡毫克当量(MME)/天。
  • 对2015年1月至2021年8月现患阿片类药物使用者月度数量拟合回归模型,评估大流行影响。

主要发现

  • RA、PsA和FM的新发阿片类药物使用者从2006年的2.6、1.0和3.4/10 000人分别增至2018或2019年的4.5、1.8和8.7,2021年分别降至2.4、1.2和5.9。
  • 所有RMD的现患阿片类药物使用者自2006年增加,2018年后趋于平稳或下降,FM在2006至2021年间增加4.5倍。
  • 2006至2021年,所有RMD的MME/天增加,FM最高(≥35)。
  • COVID-19封锁期间,RA、PsA和FM的现患阿片类药物使用者趋势出现显著变化;FM趋势在大流行前上升,大流行期间开始下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate opioid prescribing trends and assess the impact of the COVID-19 pandemic on opioid prescribing in rheumatic and musculoskeletal diseases (RMDs). METHODS: Adult patients with RA, PsA, axial spondyloarthritis (AxSpA), SLE, OA and FM with opioid prescriptions between 1 January 2006 and 31 August 2021 without cancer in UK primary care were included. Age- and gender-standardized yearly rates of new and prevalent opioid users were calculated between 2006 and 2021. For prevalent users, monthly measures of mean morphine milligram equivalents (MME)/day were calculated between 2006 and 2021. To assess the impact of the pandemic, we fitted regression models to the monthly number of prevalent opioid users between January 2015 and August 2021. The time coefficient reflects the trend pre-pandemic and the interaction term coefficient represents the change in the trend during the pandemic. RESULTS: The study included 1 313 519 RMD patients. New opioid users for RA, PsA and FM increased from 2.6, 1.0 and 3.4/10 000 persons in 2006 to 4.5, 1.8 and 8.7, respectively, in 2018 or 2019. This was followed by a fall to 2.4, 1.2 and 5.9, respectively, in 2021. Prevalent opioid users for all RMDs increased from 2006 but plateaued or dropped beyond 2018, with a 4.5-fold increase in FM between 2006 and 2021. In this period, MME/day increased for all RMDs, with the highest for FM (≥35). During COVID-19 lockdowns, RA, PsA and FM showed significant changes in the trend of prevalent opioid users. The trend for FM increased pre-pandemic and started decreasing during the pandemic. CONCLUSION: The plateauing or decreasing trend of opioid users for RMDs after 2018 may reflect the efforts to tackle rising opioid prescribing in the UK. The pandemic led to fewer people on opioids for most RMDs, providing reassurance that there was no sudden increase in opioid prescribing during the pandemic.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Huang YT, Jenkins DA, Yimer BB, et al. Trends for opioid prescribing and the impact of the COVID-19 pandemic in patients with rheumatic and musculoskeletal diseases between 2006 and 2021. Rheumatology (Oxford). 2024. PMID: 37432340. doi:10.1093/rheumatology/kead346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。